Dr. Pulsipher is Division Chief, Pediatric Hematology at Intermountain Primary
Children’s Hospital and Oncology, Director of the Children’s and Adolescent Cancer
Initiative at Huntsman Cancer Institute and a Presidential Chair in Pediatric
Oncology and Hematology at the University of Utah. He is the immediate past Group
Chair of the Pediatric Transplantation and Cellular Therapy Consortium, an 86-
member international clinical trials group, and is recognized as a leading influence
in his field, receiving the PTCTC Lifetime Achievement Award in 2020. He is
currently principal or co-principal investigator of six national, multi-center studies
and a co-investigator on multiple additional clinical trials. Dr. Pulsipher has
authored more than 260 articles in peer-reviewed journals and written 17 book
chapters. His research interests include allogeneic transplantation and cell therapy
for acute leukemias, especially ALL, where he is running national research trials
aimed at testing haploidentical approaches and assessing the role of NGS-MRD in
identifying patients able to undergo less intensive BMT approaches. Dr. Pulsipher’s
work in cell therapy helped lead to the FDA approval of the first CART cell
treatment, tisagenlecleucel, and he continues to run trials in CAR T, NK, and Viral
Specific T-cell therapies. Dr. Pulsipher has also done extensive work in reduced
toxicity approaches to transplantation of both malignant and non-malignant
disorders, and has run national protocols for patients with immunodeficiencies,
HLH, and bone marrow failure. Finally, he has run several large trials assessing the
safety and Quality of Life of pediatric bone marrow donors and is he currently
running a large national trial looking at the psychological well-being of donor and
recipient families as they go through the transplant process.